• All Rooms
• Room 1
• Room 2
• Room 3
• Room 4
• Room 1+2

March 27 (Thursday)

[JS01] Joint Session 01 (MOU Session): Adult Acute Lymphoblastic Leukemia in Asia Room 1

• March 27 (Thu), 09:00-10:15
• Won Sik Lee (Inje University College of Medicine, Korea)
  Han Viet Trung (Bach Mai Hospital, Vietnam)
• 09:00-09:15 Opportunities and challenges in managing adult ALL in Vietnam Han Viet Trung (Bach Mai Hospital, Vietnam) 09:15-09:30 Adult ALL in Armenia Armine Farmazyan (Hematology Center after Prof. R. H. Yeolyan, Armenia) 09:30-09:45 Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand Weerapat Owattanapanich (Faculty of Siriraj Hospital, Mahidol University, Thailand) 09:45-10:00 Adult ALL in Korea Ik Chan Song (Chungnam National University College of Medicine, Korea) 10:00-10:15 Discussion

[SS01] Scientific Session 01: Improving Outcomes in Challenging Pediatric Leukemia Room 2

• March 27 (Thu), 09:00-10:15
• Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
  Kyung-Ha Ryu (Ewha Womans University College of Medicine, Korea)
• 09:00-09:25 Diagnosis and treatment of ph-like ALL in children and young adults Thai Hoa Tran (Université de Montréal, Canada) 09:25-09:50 Advances in the genetics of Down syndrome-related myeloid leukemia Etsuro Ito (Hirosaki University Graduate School of Medicine, Japan) 09:50-10:15 Towards improving outcomes for high risk pediatric acute myeloid leukemia Todd Cooper (University of Washington, USA)

[SS02] Scientific Session 02: Overcoming the Resistance Mechanisms of Multiple Myeloma Room 3

• March 27 (Thu), 09:00-10:15
• Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
  Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)
• 09:00-09:25 Immune therapy and the bone marrow microenvironment in multiple myeloma Hearn Jay Cho (Icahn School of Medicine at Mount Sinai, USA) 09:25-09:50 Mechanisms of antigen escape after T-cell based immunotherapies Paola Neri (University of Calgary, Canada) 09:50-10:15 Cellular immunotherapy platforms in multiple myeloma Sung-Hoon Jung (Chonnam National University Medical School, Korea)

[ES01] Education Session 01: Understanding the Fundamentals of Myelodysplastic Syndrome KOR Room 4

• March 27 (Thu), 09:00-10:15
• Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea)
  Yong Park (Korea University College of Medicine, Korea)
• 09:00-09:25 Tracing the changes: MDS risk stratification Seo-Yeon Ahn (Chonnam National University Medical School, Korea) 09:25-09:50 Managing MDS with HMAs following the AZA-001 trial Silvia Park (College of Medicine, The Catholic University of Korea, Korea) 09:50-10:15 Approved MDS treatments beyond HMAs Junshik Hong (Seoul National University College of Medicine, Korea)

[PL01] Plenary Lecture 01 Room 1+2

• March 27 (Thu), 10:30-11:15
• Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
• 10:30-11:15 Myeloproliferative Neoplasms: 2025 Update Ayalew Tefferi (Mayo Clinic, USA)

[PS01] Presidential Symposium 01 Room 1+2

• March 27 (Thu), 11:15-12:00
• Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
• 11:15-12:00 CAR T-cell Therapy for Lymphomas: Current and Future Trends Sattva S Neelapu (The University of Texas MD Anderson Cancer Center, USA)

[SY01] Satellite Symposium 01: Handok Inc. Room 1

• March 27 (Thu), 12:15-13:05
• Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
• 12:15-13:05 Expanding Horizons in PNH Treatment: Pegcetacoplan in Proximal Inhibition Silvia Park (College of Medicine, The Catholic University of Korea, Korea)

[SY02] Satellite Symposium 02: ROCHE KOREA Room 2

• March 27 (Thu), 12:15-13:05
• Deok Hwan Yang (Chonnam National University Medical School, Korea)
• 12:15-13:05 Recent Insights on DLBCL Treatment: Focused on Glofitamab and Polatuzumab Andrew Davies (University of Southampton, UK)

[SY03] Satellite Symposium 03: BMS Pharmaceutical Korea Room 3

• March 27 (Thu), 12:15-13:05
• Jin Seok Kim (Yonsei University College of Medicine, Korea)
• 12:15-13:05 Optimizing Current Treatment Strategies in Relapsed/Refractory Multiple Myeloma Wee Joo Chng (National University of Singapore, Singapore)

[SY04] Satellite Symposium 04: GlaxoSmithKline Room 4

• March 27 (Thu), 12:15-13:05
• Sung-Yong Kim (Konkuk University School of Medicine, Korea)
• 12:15-13:05 Omjjara: Redefine the Fundamental Treatment for Myelofibrosis Patients with Anemia Harry Gill (The University of Hong Kong, Hong Kong)

[OP01] Oral Presentation 01: Acute Leukemia (AML) Room 1

• March 27 (Thu), 13:55-15:10
• Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
  Hyeon Jin Park (National Cancer Center, Korea)
• 13:55-14:07 Intensity-adjusted salvage chemotherapy plus FLT3-inhibitor gilteritinib in relapsed/refractory acute myeloid leukemia with mutated FLT3-ITD/TKD (SAPPHIRE-G) Hawk Kim (Gachon University College of Medicine, Korea) 14:07-14:19 Deciphering clinical and genetic aspects of TP53-mutated acute myeloid leukemia Songyi Park (Seoul National University Boramae Medical Center, Korea) 14:19-14:31 Functional characteristics and clinical implications of CD39-expressing T cell populations in patients with newly diagnosed acute myeloid leukemia Nayeon Seong (Korea University College of Medicine, Korea) 14:31-14:43 Genetic prognostic factors in pediatric core binding factor acute myeloid leukemia Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea) 14:43-14:55 The efficacy of hypomethylating agent and venetoclax treatment for secondary acute myeloid leukemia patients evolving from myelodysplastic syndrome or chronic myelomocytic leukemia PilYong Lim (College of Medicine, The Catholic University of Korea, Korea) 14:55-15:07 Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of trophy group Yi Xia (Peking University People's Hospital, China)

[OP02] Oral Presentation 02: Laboratory Hematology Room 2

• March 27 (Thu), 13:55-15:10
• Sun-Young Kong (National Cancer Center, Korea)
  Jaewoo Song (Yonsei University College of Medicine, Korea)
• 13:55-14:07 Representativeness of clone size measured by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in multiple myeloma Hyeseong Ryu (University of Ulsan College of Medicine, Korea) 14:07-14:19 Evaluation of two NGS-based somatic hypermutation detection assay in chronic lymphocytic leukemia Yehyun Kang (Yonsei University College of Medicine, Korea) 14:19-14:31 Development of amplicon-based NGS assay for detection of BCR::ABL1 kinase domain mutation TaekGyu Lee (Yonsei University College of Medicine, Korea) 14:31-14:43 Spectrum of TP53 mutation in hematologic malignancies Seo Yoon Jang (Seoul National University Hospital, Korea) 14:43-14:55 An NGS-based analysis of the genomic landscapes of beta-globin gene cluster, the beta-LCR, and HbF modifiers yields new phenotype regulators and diagnostic data on symptomatic beta-thalassemia Prashant Sharma (Postgraduate Institute of Medical Education and Research, India) 14:55-15:07 NG2 expression pattern and its predictive value for different types of KMT2A translocations in acute myeloid leukemia and B acute lymphoblastic leukemia Sweta Rajpal (Tata Memorial Centre, India)

[OP03] Oral Presentation 03: Lymphoma Room 3

• March 27 (Thu), 13:55-15:10
• Jeong-Ok Lee (Seoul National University College of Medicine, Korea)
  Seong Hyun Jeong (Ajou University School of Medicine, Korea)
• 13:55-14:07 Bendamustine-rituximab (R-benda) in first-line treatment for advanced stage follicular lymphoma presented better clinical outcomes compared to other Rituximab-based regimen Gi June Min (College of Medicine, The Catholic University of Korea, Korea) 14:07-14:19 High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide followed by autologous stem cell transplantation in patients with primary or secondary central nervous system lymphoma Dong Hyun Kim (Seoul National University College of Medicine, Korea) 14:19-14:31 Treatment patterns and survival outcomes in patients with mantle cell lymphoma: Interim report of the Asia-Pacific multinational prospective registry study Hyungwoo Cho (University of Ulsan College of Medicine, Korea) 14:31-14:43 Exploring microbiome analysis as the predictive marker of treatment resistance in relapsed/refractory diffuse large B cell lymphoma patients treated with CD19 CAR-T cell therapies Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea) 14:43-14:55 Seven-year overall survival from ECHELON-1: A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) 14:55-15:07 Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicenter analysis in China Yuewen Wang (Peking University People's Hospital, China)

[OP04] Oral Presentation 04: Chronic Myeloid Leukemia / Myeloproliferative Neoplasm / Myelodysplastic Syndrome Room 4

• March 27 (Thu), 13:55-15:10
• Jun Eun Park (Korea University College of Medicine, Korea)
  Joon Seong Park (Ajou University School of Medicine, Korea)
• 13:55-14:07 Asciminib provides better efficacy and favorable safety and tolerability vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia: results from the ASC4FIRST study East Asian subgroup Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea) 14:07-14:19 Clinical outcomes in patients with myelodysplastic syndromes carrying the germline DDX41 mutation Hohyung Nam (College of Medicine, The Catholic University of Korea, Korea) 14:19-14:31 Ropeginterferon in low-risk patients with polycythemia vera Ji Yun Lee (Seoul National University College of Medicine, Korea) 14:31-14:43 The clinical diagnostic value of neutrophil–to-lymphocyte ratio in patients with erythrocytosis Seug Yun Yoon (Soonchunhyang University College of Medicine, Korea) 14:43-14:55 Novel genetic aberrations in chronic myeloid leukemia in adolescents and young adults Priyavadhana Balasubramanian (All India Institute of Medical Sciences, India) 14:55-15:07 An insight into treatment free remission (TFR) outcomes in chronic myeloid leukaemia (CML) - A tertiary centre experience in Malaysia Christopher Chin Keong Liam (Hospital Sultanah Aminah, Malaysia)

[JS02] Joint Session 02 (EHA-KSH): Acute Myeloid Leukemia - Research and Practice Room 1

• March 27 (Thu), 15:25-16:40
• Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)
  Brian Huntly (University of Cambridge, UK)
• 15:25-15:40 Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC) Brian Huntly (University of Cambridge, UK) 15:40-15:55 Treatment of AML in Korea June-Won Cheong (Yonsei University College of Medicine, Korea) 15:55-16:10 Genetics guiding treatment in AML Hartmut Döhner (Ulm University Hospital, Germany) 16:10-16:25 The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study Jae-Sook Ahn (Chonnam National University Medical School, Korea) 16:25-16:40 Discussion

[SS03] Scientific Session 03: Updates in Cancer-Associated Venous Thromboembolism Room 2

• March 27 (Thu), 15:25-16:40
• Soo-Mee Bang (Seoul National University College of Medicine, Korea)
  Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)
• 15:25-15:50 When not to use direct oral anticoagulants Jeffrey I. Weitz (McMaster University, Canada) 15:50-16:15 Managing patients with cancer associated venous thromboembolism Robert D. McBane II (Mayo College of Medicine, USA) 16:15-16:40 Risk assessment and thromboprophylaxis for cancer-associated VTE Ingrid Pabinger-Fasching (Medical University of Vienna, Austria)

[SS04] Scientific Session 04: Advancements in Peripheral T-cell Lymphoma: From Biological Insights to Innovative Treatments Room 3

• March 27 (Thu), 15:25-16:40
• Jae Yong Kwak (Jeonbuk National University Medical School, Korea)
  Deok Hwan Yang (Chonnam National University Medical School, Korea)
• 15:25-15:50 Turning the corner in the management of the PTCL Owen A O'Connor (University of Virginia Comprehensive Cancer Center, USA) 15:50-16:15 Recent updates and future in the management of R/R PTCL Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) 16:15-16:40 The development of new agents in T-cell lymphoma Hyun Jung Lee (Kyung Hee University College of Medicine, Korea)

[ES02] Education Session 02: Basic Understanding and Application of Artificial Intelligence KOR Room 4

• March 27 (Thu), 15:25-16:40
• Hyery Kim (University of Ulsan College of Medicine, Korea)
  Joon Ho Moon (Kyungpook National University School of Medicine, Korea)
• 15:25-15:50 AI everywhere Auk Kim (Department of Computer Science and Engineering, Kangwon National University, Korea) 15:50-16:15 Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation Sang-Hyun Hwang (University of Ulsan College of Medicine, Korea) 16:15-16:40 Generative AI use case for medical research: HRS (healthcare data research suite) Soo-Yong Shin (Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea)

[SS05] Scientific Session 05: Red Blood Cells in Myeloproliferative Neoplasm Room 1

• March 27 (Thu), 16:55-18:10
• Sung-Yong Kim (Konkuk University School of Medicine, Korea)
  Jong Ho Won (Soonchunhyang University College of Medicine, Korea)
• 16:55-17:20 Iron metabolism in JAK2-mutant myeloproliferative neoplasms Radek C. Skoda (Dan L Duncan Comprehensive Cancer Center, USA) 17:20-17:45 Hepcidin in the pathophysiology of and as treatment for polycythemia vera Yelena Z. Ginzburg (Icahn School of Medicine at Mount Sinai, USA) 17:45-18:10 Anemia and JAK inhibitors Jean-Jaques Kiladjian (Hôpital Saint-Louis, France)

[SS06] Scientific Session 06: Advances and Challenges in Histiocytic Diseases: A comprehensive Update Room 2

• March 27 (Thu), 16:55-18:10
• Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea)
  Ho Joon Im (University of Ulsan College of Medicine, Korea)
• 16:55-17:20 Innovations in HLH therapy: Beyond HLH94 Michelle Hermiston (VinUniversity, Vietnam / UCSF, USA) 17:20-17:45 Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies Oussama Abla (The Hospital for Sick Children, Canada) 17:45-18:10 From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes Melissa Hines (St. Jude Children’s Research Hospital, USA)

[SS07] Scientific Session 07: Breaking New Ground in Acute Myeloid Leukemia Room 3

• March 27 (Thu), 16:55-18:10
• Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
  June-Won Cheong (Yonsei University College of Medicine, Korea)
• 16:55-17:20 Understanding and overcoming resistance in AML Dong-Yeop Shin (Seoul National University College of Medicine, Korea) 17:20-17:45 Exploring immune checkpoint targets beyond PD-1 and PD-L1 in AML (LAIR-1 agonism as a novel therapy for acute myeloid leukemia) Tae Kon Kim (Vanderbilt University Medical Center, USA) 17:45-18:10 Implementing a functional precision medicine for AML patients Mika Kontro (Helsinki University Hospital, Finland)

[ES03] Education Session 03: Turning Ideas into Successful Clinical Trial: A Practical Approach KOR Room 4

• March 27 (Thu), 16:55-18:10
• Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
  Hyeon-Seok Eom (National Cancer Center, Korea)
• 16:55-17:20 Crafting a successful investigator-initiated study proposal: Key elements and strategies Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea) 17:20-17:45 Current trends of big data research using the Korean national health information database Kyungdo Han (Department of Statistics and Actuarial Science, Soongsil University, Korea) 17:45-18:10 Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting Jeong-Ok Lee (Seoul National University College of Medicine, Korea)